2278 - Treatment Patterns and Overall Survival in Patients With BRAF-Mutated Metastatic Non-Small Cell Lung Cancer

Background

BRAF mutations are observed in 2% – 4% of all non-small cell lung cancer (NSCLC) patients, but few targeted therapies are available, with limited practice level data on utilization and outcomes. This study therefore aims to document, from a “real-world” perspective, treatment patterns, testing characteristics, and overall survival (OS) in patients with BRAF-positive (BRAF+) metastatic NSCLC (mNSCLC).

Methods

This was a multinational, retrospective medical record review of patients with BRAF+ mNSCLC (diagnosed 2005-2016) in EU, Canada and S Korea. Patients were ≥18 years of age at mNSCLC diagnosis (“index”) and had ≥12 months of post-index follow-up time, except for patients who died sooner. Study measures included baseline patient characteristics, timing of mutational testing, systemic therapies for mNSCLC, and OS. Kaplan-Meier analyses were conducted to descriptively analyze OS dependent on treatment with a BRAF inhibitor (BRAFi).

Results

Of all patients (n = 76; median age = 64 years), 24% had been tested for BRAF mutation at index; 61% had been tested before initiating the first line of therapy (LOT-1), 79% before LOT-2 and 85% before LOT-3. Chemotherapy was the most common first (76%), second (46%), and third (38%) LOT. BRAFi (+/- a MEK inhibitor) was received by 53% of all patients initiating a systemic therapy (n = 66) in any LOT. Median OS from index was 19.4 months (95% CI = 13.3-22.8) in all patients, 23.4 months (95% CI = 18.5-98.4) in patients treated with BRAFi, and 11.8 months (95% CI = 4.5-20.0) in patients not treated with BRAFi, in any LOT. Three-year OS rates from LOT initiation are summarized in the table.

Conclusions

The majority of confirmed BRAF+ mNSCLC patients were tested for BRAF mutation before initiation of LOT-1. Chemotherapy was the predominant frontline therapy and BRAFi was utilized mainly in second and later LOTs. Median OS was numerically higher in patients treated with BRAFi versus patients not treated with BRAFi in any LOT.

Clinical trial identification

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation.

Funding

Novartis Pharmaceuticals Corporation.

Editorial Acknowledgement

Disclosure

R.K. Goyal: Employee: RTI Health Solutions, which has received contract research funding in the past 2 years from the following companies for which author has or currently has conducting health outcomes research projects: Novartis, Pfizer, AstraZeneca, Eli Lilly and Company, and Amgen. J. Wolf: Consulting or advisory role to disclose: Abbvie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche; Research funding: BMS, MSD, Novartis, Pfizer; Travel, accommodations, or expenses: Abbvie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche. J. Mazieres: Consulting or advisory role: AstraZeneca, Roche, BMS, MSD, Novartis, Pfizer; Research funding: AstraZeneca, Roche, BMS; Travel, accommodations, or expenses: Roche, BMS, Novartis, Pfizer. C. Chouaid: Honoraria: AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis and Amgen; Consulting or advisory role: AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis and Amgen; Research funding: AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis and Amgen; Travel, accommodations, or expenses: AstraZeneca, Boehringer Ingelheim, Roche, BMS, MSD, Lilly. K.L. Davis: Employee: RTI Health Solutions, which has received contract research funding in the past 2 years from the following companies for which I have (or currently are) conducting health outcomes research projects: Novartis, Pfizer, AstraZeneca, Shire, Eli Lilly and Company, Takeda, Celgene. S. Knoll: Stock or other ownership: Novartis, GSK, Roche, Merck KGA, Gilead, Incyte. All other authors have declared no conflicts of interest.Table: 1489P

OS rate from start of LOTs